129 related articles for article (PubMed ID: 26020569)
21. Serum levels of the CC chemokines CCL2, CCL5, and CCL11 in food allergic children with different clinical manifestations.
Radman M; Hassanshahi G; Vazirinejad R; Arababadi MK; Karimabad MN; Khorramdelazad H; Rafatpanah H; Iranmanesh F; Hakimizadeh E; Ahmadi Z
Inflammation; 2013 Jun; 36(3):561-6. PubMed ID: 23180368
[TBL] [Abstract][Full Text] [Related]
22. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.
Volpato M; Perry SL; Marston G; Ingram N; Cockbain AJ; Burghel H; Mann J; Lowes D; Wilson E; Droop A; Randerson-Moor J; Coletta PL; Hull MA
Oncotarget; 2016 May; 7(19):28139-50. PubMed ID: 27058904
[TBL] [Abstract][Full Text] [Related]
23. Chemokine MCP1/CCL2 and RANTES/CCL5 gene polymorphisms influence Henoch-Schönlein purpura susceptibility and severity.
Yu HH; Liu PH; Yang YH; Lee JH; Wang LC; Chen WJ; Chiang BL
J Formos Med Assoc; 2015 Apr; 114(4):347-52. PubMed ID: 25839768
[TBL] [Abstract][Full Text] [Related]
24. C-C motif chemokine ligand 5 and C-C chemokine receptor type 5: possible diagnostic application in breast cancer patients.
Dąbrowska E; Przylipiak A; Zajkowska M; Piskór BM; Borowik-Zaręba A; Ławicki S
Acta Biochim Pol; 2020 Nov; 67(4):539-449. PubMed ID: 33245226
[TBL] [Abstract][Full Text] [Related]
25. Gnetin C suppresses double-stranded RNA-induced C-C motif chemokine ligand 2 (CCL2) and CCL5 production by inhibiting Toll-like receptor 3 signaling pathway.
Yoshida H; Imaizumi T; Matsumiya T; Seya K; Kawaguchi S; Tanaka H
Biomed Res; 2018; 39(5):231-240. PubMed ID: 30333430
[TBL] [Abstract][Full Text] [Related]
26. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer.
Zhuo C; Wu X; Li J; Hu D; Jian J; Chen C; Zheng X; Yang C
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29784873
[TBL] [Abstract][Full Text] [Related]
27. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.
Sucur A; Jajic Z; Artukovic M; Matijasevic MI; Anic B; Flegar D; Markotic A; Kelava T; Ivcevic S; Kovacic N; Katavic V; Grcevic D
Arthritis Res Ther; 2017 Jun; 19(1):142. PubMed ID: 28619088
[TBL] [Abstract][Full Text] [Related]
28. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease.
Bartosik-Psujek H; Stelmasiak Z
Eur J Neurol; 2005 Jan; 12(1):49-54. PubMed ID: 15613147
[TBL] [Abstract][Full Text] [Related]
29. Equine herpesvirus type-1 modulates CCL2, CCL3, CCL5, CXCL9, and CXCL10 chemokine expression.
Wimer CL; Damiani A; Osterrieder N; Wagner B
Vet Immunol Immunopathol; 2011 Apr; 140(3-4):266-74. PubMed ID: 21349590
[TBL] [Abstract][Full Text] [Related]
30. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination.
Sugasawa H; Ichikura T; Kinoshita M; Ono S; Majima T; Tsujimoto H; Chochi K; Hiroi S; Takayama E; Saitoh D; Seki S; Mochizuki H
Int J Cancer; 2008 Jun; 122(11):2535-41. PubMed ID: 18246596
[TBL] [Abstract][Full Text] [Related]
31. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease.
Reale M; Iarlori C; Feliciani C; Gambi D
J Alzheimers Dis; 2008 Jun; 14(2):147-59. PubMed ID: 18560127
[TBL] [Abstract][Full Text] [Related]
32. Postoperative elevation in the plasma CCL2 level is a predictive biomarker of colorectal cancer recurrence.
Fukunaga M; Mimori K; Masuda T; Hu Q; Yamada K; Mori M
Surg Today; 2021 Oct; 51(10):1671-1681. PubMed ID: 33797637
[TBL] [Abstract][Full Text] [Related]
33. Innate signaling mechanisms controlling Mycobacterium chelonae-mediated CCL2 and CCL5 expression in macrophages.
Kim YS; Kim JH; Woo M; Kim TS; Sohn KM; Lee YH; Jo EK; Yuk JM
J Microbiol; 2015 Dec; 53(12):864-74. PubMed ID: 26626357
[TBL] [Abstract][Full Text] [Related]
34. Serum chemokine ligand 5 (CCL5/RANTES) level might be utilized as a predictive marker of tumor behavior and disease prognosis in patients with gastric adenocarcinoma.
Sima AR; Sima HR; Rafatpanah H; Hosseinnezhad H; Ghaffarzadehgan K; Valizadeh N; Mehrabi Bahar M; Hakimi HR; Masoom A; Noorbakhsh A; Razavi Satvati N; Raziee HR
J Gastrointest Cancer; 2014 Dec; 45(4):476-80. PubMed ID: 25301002
[TBL] [Abstract][Full Text] [Related]
35. Adiponectin stimulates release of CCL2, -3, -4 and -5 while the surface abundance of CCR2 and -5 is simultaneously reduced in primary human monocytes.
Neumeier M; Bauer S; Brühl H; Eisinger K; Kopp A; Abke S; Walter R; Schäffler A; Buechler C
Cytokine; 2011 Dec; 56(3):573-80. PubMed ID: 21890375
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of urinary and serum level of chemokine (C-C motif) ligand 2 as a potential biomarker in canine urothelial tumours.
Shimizu N; Hamaide A; Dourcy M; Noël S; Clercx C; Teske E
Vet Comp Oncol; 2019 Mar; 17(1):11-20. PubMed ID: 30588734
[TBL] [Abstract][Full Text] [Related]
37. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression.
Mandal PK; Biswas S; Mandal G; Purohit S; Gupta A; Majumdar Giri A; Roy Chowdhury S; Bhattacharyya A
Immunobiology; 2018 Feb; 223(2):151-161. PubMed ID: 29107385
[TBL] [Abstract][Full Text] [Related]
38. Low serum levels of CCL2 are associated with worse prognosis in patients with Acute Coronary Syndrome: 2-year survival analysis.
Leocádio PCL; Menta PLDR; Dias MTS; Fraga JR; Goulart AC; Santos IS; Lotufo PA; Bensenor IM; Alvarez-Leite JI
Biomed Pharmacother; 2019 Jan; 109():1411-1416. PubMed ID: 30551392
[TBL] [Abstract][Full Text] [Related]
39. Pneumoperitoneum Modifies Serum and Tissue CCL2-CCL5 Expression in Mice.
Papparella A; Noviello C; Ranucci S; Paciello O; Papparella S; De Biase D; Cirillo G; Umano GR
JSLS; 2020; 24(2):. PubMed ID: 32508487
[TBL] [Abstract][Full Text] [Related]
40. Human telomerase reverse transcriptase recruits the β-catenin/TCF-4 complex to transactivate chemokine (C-C motif) ligand 2 expression in colorectal cancer.
Chen S; Yang L; Dong H; Guo H
Biomed Pharmacother; 2019 Apr; 112():108700. PubMed ID: 30970512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
